APA (7th ed.) Citation

Suthar, M. S., Manning, K. E., Ellis, M. L., Jain, S., Bechnak, K., Vander Velden, J., . . . Moreno, A. (2025). The KP.2-adapted COVID-19 vaccine improves neutralising activity against the XEC variant. The Lancet infectious diseases, 25(3), e122-e123. https://doi.org/10.1016/S1473-3099(25)00007-6

Chicago Style (17th ed.) Citation

Suthar, Mehul S., et al. "The KP.2-adapted COVID-19 Vaccine Improves Neutralising Activity Against the XEC Variant." The Lancet Infectious Diseases 25, no. 3 (2025): e122-e123. https://doi.org/10.1016/S1473-3099(25)00007-6.

MLA (9th ed.) Citation

Suthar, Mehul S., et al. "The KP.2-adapted COVID-19 Vaccine Improves Neutralising Activity Against the XEC Variant." The Lancet Infectious Diseases, vol. 25, no. 3, 2025, pp. e122-e123, https://doi.org/10.1016/S1473-3099(25)00007-6.